AIMC Topic: Carcinoma, Non-Small-Cell Lung

Clear Filters Showing 81 to 90 of 404 articles

Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.

Lung cancer (Amsterdam, Netherlands)
BACKGROUND: Manual extraction of real-world clinical data for research can be time-consuming and prone to error. We assessed the feasibility of using natural language processing (NLP), an AI technique, to automate data extraction for patients with ad...

Explainable Machine Learning to Predict Treatment Response in Advanced Non-Small Cell Lung Cancer.

JCO clinical cancer informatics
PURPOSE: Immune checkpoint inhibitors (ICIs) have demonstrated promise in the treatment of various cancers. Single-drug ICI therapy (immuno-oncology [IO] monotherapy) that targets PD-L1 is the standard of care in patients with advanced non-small cell...

Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience.

Lung cancer (Amsterdam, Netherlands)
BACKGROUND: Artificial intelligence (AI) models are emerging as promising tools to identify predictive features among data coming from health records. Their application in clinical routine is still challenging, due to technical limits and to explaina...

Radiomics for differentiating adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer beyond nodule morphology in chest CT.

Scientific reports
Distinguishing between primary adenocarcinoma (AC) and squamous cell carcinoma (SCC) within non-small cell lung cancer (NSCLC) tumours holds significant management implications. We assessed the performance of radiomics-based models in distinguishing ...

Artificial neural network systems to predict the response to sintilimab in squamous-cell non-small-cell lung cancer based on data of ORIENT-3 study.

Cancer immunology, immunotherapy : CII
BACKGROUND: Existing biomarkers and models for predicting response to programmed cell death protein 1 monoclonal antibody in advanced squamous-cell non-small cell lung cancer (sqNSCLC) did not have enough accuracy. We used data from the ORIENT-3 stud...

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era.

International journal of molecular sciences
Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS) ...

Exploring tumor microenvironment interactions and apoptosis pathways in NSCLC through spatial transcriptomics and machine learning.

Cellular oncology (Dordrecht, Netherlands)
BACKGROUND: The most common type of lung cancer is non-small cell lung cancer (NSCLC), accounting for 85% of all cases. Programmed cell death (PCD), an important regulatory mechanism for cell survival and homeostasis, has become increasingly prominen...

High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC.

Frontiers in immunology
INTRODUCTION: Tumor-infiltrating lymphocytes are both prognostic and predictive biomarkers for immunotherapy response. However, less is known about the survival benefits oftheir subpopulations.